IOVS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

(Investigative Ophthalmology and Visual Science. 2006;47:2125-2134.)
© 2006 by The Association for Research in Vision and Ophthalmology, Inc.
doi:10.1167/iovs.05-1096
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (25)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Banin, E.
Right arrow Articles by Friedlander, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Banin, E.
Right arrow Articles by Friedlander, M.

T2-TrpRS Inhibits Preretinal Neovascularization and Enhances Physiological Vascular Regrowth in OIR as Assessed by a New Method of Quantification

Eyal Banin,1,2,3 Michael I. Dorrell,1,3 Edith Aguilar,1 Matthew R. Ritter,1 Christopher M. Aderman,1 Alexandra C. H. Smith,1 Jeffrey Friedlander,1 and Martin Friedlander1

1From the Department of Cell Biology, The Scripps Research Institute, La Jolla, California; and the 2Department of Ophthalmology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.

PURPOSE. A carboxyl-terminal fragment of tryptophan tRNA synthetase (T2-TrpRS) has demonstrated potent angiostatic activity during retinal developmental neovascularization in vivo. The effects of T2-TrpRS on pathologic neovascularization were tested and compared with a potent VEGF antagonist using the mouse model of oxygen-induced retinopathy (OIR).

METHODS. C57BL/6J mice were transiently exposed to hyperoxic conditions (75% O2) between postnatal day 7 (P7) and P12 and then returned to room air. Retinas were isolated, blood vessels stained with isolectin Griffonia simplicifolia, images of retinal whole-mounts acquired, and the area of vascular obliteration and extent of preretinal neovascularization quantified. This method was compared to the commonly used method of OIR quantification in which the number of pre-inner limiting membrane (ILM) nuclei is counted in serial sections of whole eyes. To assess the angiostatic activity of T2-TrpRS, mice were injected intravitreally at P12 with either T2-TrpRS, a VEGF aptamer, or vehicle (PBS) alone, and the effects on area of obliteration and on preretinal neovascular tuft formation were assessed.

RESULTS. Using a modified method of quantification in the mouse OIR model based on images of isolectin-stained retinal wholemounts, we were able to assess reliably and consistently both vascular obliteration and preretinal neovascular tuft formation in the same specimen. T2-TrpRS demonstrated potent angiostatic activity, reducing the appearance of pathologic neovascular tufts by up to 90%. Surprisingly, T2-TrpRS also enhanced physiological revascularization of the obliterated retinal vasculature, reducing these areas by up to 60% compared with PBS-injected eyes. In contrast, the VEGF antagonist, while similarly reducing preretinal neovascular tuft formation, did not enhance revascularization of the obliterated areas.

CONCLUSIONS. Use of a rapid, quantifiable method to assess the effect of T2-TrpRS on retinal angiogenesis in the OIR model demonstrates the importance of a quantification system that permits simultaneous analysis of a drug’s effect on vascular obliteration as well as on preretinal neovascularization. The results obtained using this method suggest enhanced clinical value for compounds such as T2-TrpRS that not only inhibit pathologic neovascularization, but also facilitate physiological revascularization of ischemic tissue.




This article has been cited by other articles:


Home page
 Am. J. Pathol.Home page
K. E. Hubert, M. H. Davies, A. J. Stempel, T. S. Griffith, and M. R. Powers
TRAIL-Deficient Mice Exhibit Delayed Regression of Retinal Neovascularization
Am. J. Pathol., December 1, 2009; 175(6): 2697 - 2708.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
H. Zhao, H. Jin, Q. Li, Q. Gu, Z. Zheng, H. Wu, S. Ye, X. Sun, X. Xu, and P. C. P. Ho
Inhibition of Pathologic Retinal Neovascularization by a Small Peptide Derived from Human Apolipoprotein(a)
Invest. Ophthalmol. Vis. Sci., November 1, 2009; 50(11): 5384 - 5395.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
M. Guma, J. Rius, K. X. Duong-Polk, G. G. Haddad, J. D. Lindsey, and M. Karin
Genetic and pharmacological inhibition of JNK ameliorates hypoxia-induced retinopathy through interference with VEGF expression
PNAS, May 26, 2009; 106(21): 8760 - 8765.
[Abstract] [Full Text] [PDF]

Home page
 Circ. Res.Home page
A. Higuchi, K. Ohashi, S. Kihara, K. Walsh, and N. Ouchi
Adiponectin Suppresses Pathological Microvessel Formation in Retina Through Modulation of Tumor Necrosis Factor-{alpha} Expression
Circ. Res., May 8, 2009; 104(9): 1058 - 1065.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
J. Chen, K. M. Connor, C. M. Aderman, K. L. Willett, O. P. Aspegren, and L. E. H. Smith
Suppression of Retinal Neovascularization by Erythropoietin siRNA in a Mouse Model of Proliferative Retinopathy
Invest. Ophthalmol. Vis. Sci., March 1, 2009; 50(3): 1329 - 1335.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
M. H. Davies, A. J. Stempel, and M. R. Powers
MCP-1 Deficiency Delays Regression of Pathologic Retinal Neovascularization in a Model of Ischemic Retinopathy
Invest. Ophthalmol. Vis. Sci., September 1, 2008; 49(9): 4195 - 4202.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
S. G. Park, P. Schimmel, and S. Kim
Aminoacyl tRNA synthetases and their connections to disease
PNAS, August 12, 2008; 105(32): 11043 - 11049.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
J. Ruiz-Ederra and A. S. Verkman
Aquaporin-1 Independent Microvessel Proliferation in a Neonatal Mouse Model of Oxygen-Induced Retinopathy
Invest. Ophthalmol. Vis. Sci., October 1, 2007; 48(10): 4802 - 4810.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
H. Uusitalo-Jarvinen, T. Kurokawa, B. M. Mueller, P. Andrade-Gordon, M. Friedlander, and W. Ruf
Role of Protease Activated Receptor 1 and 2 Signaling in Hypoxia-Induced Angiogenesis
Arterioscler Thromb Vasc Biol, June 1, 2007; 27(6): 1456 - 1462.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
M. I. Dorrell, E. Aguilar, L. Scheppke, F. H. Barnett, and M. Friedlander
Combination angiostatic therapy completely inhibits ocular and tumor angiogenesis
PNAS, January 16, 2007; 104(3): 967 - 972.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by the Association for Research in Vision and Ophthalmology